Moderate movements with positive signs in the European stock markets on Monday in the last – and festive – week of the year, while some markets remained closed.
Investors’ interest remained focused on concerns about the restrictive measures that many countries are forced to bring back into the world to stem the new pandemic wave and their potential impact on central bank economic recovery and tighter monetary policy, amid indications that Omicron mutation is milder than previous coronavirus strains, such as Delta.
New studies in South Africa and the United Kingdom last week showed that Omicron has a reduced risk of hospitalization and serious illness. In the UK, new cases remain high, although today they have fallen below 100,000.
The British government today assured that no new restrictions will be imposed in England before the new year due to Covid-19. “When we enter the new year, we will certainly see if we need to take further action,” he added. According to Javid, the Omicron variant is responsible for about 90% of cases in England.
Similar cases have been reported in France, where French Prime Minister Jean-Castex and Health Minister Olivier Veran are expected to provide details on new pandemic measures.
In this climate, the pan-European index Stoxx 600 recorded a rise of 0.62% to 485.49 points, moving to a one-month high, with the technology sector and the healthcare and construction sectors leading the way in profits. After falling 4% in 2020, the Stoxx 600 is on track to “jump” 21.7% in 2021.
In the individual dashboard, the German DAX strengthened by 0.5% to 15,835.25 points and the French CAC 40 added 0.26% to 7,140.39 points.
In the periphery, the Spanish IBEX 35 gained 0.68% to 8,622.10 points and the Italian FTSE MIB recorded an increase of 0.8% to 27,231.20 points.
The market in the UK was closed today due to a holiday.
In the individual shares, the high-tech industrial group Groupe Gorgé jumped 6.4% after the confirmation of an indicative offer for the acquisition of iXblue.
Roche added 0.9% after Swiss drug regulator Swissmedic approved Ronapreve, an antibody treatment co-developed with Regeneron for the treatment of patients with covid-19.
.
I am Sophia william, author of World Stock Market. I have a degree in journalism from the University of Missouri and I have worked as a reporter for several news websites. I have a passion for writing and informing people about the latest news and events happening in the world. I strive to be accurate and unbiased in my reporting, and I hope to provide readers with valuable information that they can use to make informed decisions.
